Page 24 - 《中国药房》2021年10期
P. 24
露-反应关系。虽然可穿戴设备在科学性、伦理和隐私 sites/default/files/E11_R1_Addendum.pdf.
等方面存在挑战,但其能以较低成本收集患者的纵向数 [ 8 ] FDA. Framework for FDA’s real-world evidence program
据来填补儿科证据的空白,尤其是在已知患者临床结局 [EB/OL]. [2020-09-07]. https://www.fda.gov/media/120-
和生物标志物的基础上 。 060/download.
[68]
[ 9 ] BAUMFELD A E,REYNOLDS R,CAUBEL P,et al. Trial
6.4 提高研究设计的合理性
designs using real-world data:the changing landscape of
对于真实世界研究,无论类型如何,都应首先考虑
the regulatory approval process[J]. Pharmacoepidemiol
研究设计带来的风险。研究者应与参与者在内的利益
Drug Saf,2020,29(10):1201-1212.
相关者进行协商,修改知情同意书语言、设计流程,以最
[10] RWE Navigator. What is real-world evidence(RWE)?[EB/
大程度地减少漏洞、规避风险;并应保证研究设计的完
OL].[2020-09-07]. https://rwe-navigator.eu/use-real-world-
整性和合法性,并在研究过程中与儿科患者及其父母建 evidence/rwe-importance-in-medicine-development/.
[69]
立信任,准确地向潜在的研究参与者传达研究内容 。 [11] US Department of Health,Education,and Welfare. Gui-
7 结语 dance for industry:general considerations for the clinical
由于儿科人群的特殊性,与成人临床试验相比,开 evaluation of drugs in infants and children[EB/OL]. [2020-
展传统临床试验面临挑战。随着医疗保健信息的数字 09-07]. https://wayback.archive-it.org/7993/2019091709-
化和数据存储能力的提高,许多国家应用 RWE 开展儿 0954/https://www.fda.gov/media/71516/download.
科医药产品研发,尝试解决患者招募困难、不符合伦理 [12] CAROLINE M. US Food and Drug Administration’s re-
quirements on content and format for labeling for human
等问题,但真实世界研究在应用的过程中仍面临一些障
prescription drugs rule:1979[EB/OL]. [2020-09-20]. https://
碍,如数据收集困难及获取知情同意困难等。随着未来
embryo.asu.edu/pages/us-food-and-drug-administrations-
基础设施和数据网络的逐步建设和完善,RWE可为儿科
requirements-content-and-format-labeling-human-prescrip-
领域带来更多的机会和获益。
tion.
参考文献 [13] FDA. Food and Drug Administration guidance for indu-
[ 1 ] World Health Organization. Children are not little adults stry:the content and format for pediatric use supple-
[EB/OL]. [2020-09-20]. https://www.who.int/ceh/capacity/ ments[EB/OL].(1996-05-24)[2020-09-20]. https://www.
Children_are_not_little_adults.pdf. govinfo.gov/content/pkg/FR-1996-05-24/pdf/96-13175.pdf.
[ 2 ] RATWANI R M,MOSCOVITCH B,RISING J P. Impro- [14] FDA. Food and Drug Administration modernization act of
ving pediatric electronic health record usability and safety 1997:proceedings of 105th congress of the United States
through certification:seize the day[J]. JAMA Pediatr, of America;Washington,D.C.,USA:1997[EB/OL].
2018,172(11):1007-1008. (1997-06-05)[2021-05-09]. https://www.fda.gov/down-
[ 3 ] FDA. use of real-world evidence to support regulatory de- loads/RegulatoryInformation/Legislation/FederalFoodDrug-
cision-making for medical devices[EB/OL].(2017-08-31) andCosmeticActFDCAct/SignificantAmendmentstothe-
[2020-09-07]. https://www.fda.gov/downloads/medicalde- FDCAct/FDAMA/FullTextofFDAMAlaw/UCM089145.
vices/deviceregulationandguidance/guidancedocuments/ pdf.
ucm513027.pdf. [15] FDA. Regulations requiring manufacturers to assess the
[ 4 ] PEDEN M. World report on child injury prevention ap- safety and effectiveness of new drugs and biological pro-
peals to“keep kids safe”[J]. Int J Prev,2008,14(6): ducts in pediatric patients:final rule[EB/OL].(1998-12-02)
413-414. [2020-09-20]. https://www.govinfo.gov/content/pkg/FR-
[ 5 ] 国家药品监督管理局药品审评中心.国家药监局药审中 1998-12-02/pdf/98-31902.pdf.
心关于发布《儿童用药(化学药品)药学开发指导原则 [16] FDA. Best pharmaceuticals for children act[EB/OL]. [2020-
(试 行)》的 通 告 :2020 年 第 67 号 [EB/OL].(2020-12- 09-20]. https://www.fda.gov/science-research/pediatrics/
31)[2021-02-25]. http://www.cde.org.cn/news.do?me- best-pharmaceuticals-children-act-and-pediatric-research-
thod=viewInfoCommon&id=b40a4d0fd292259b. equity-act.
[ 6 ] 耿莹,张豪,孙艳喆,等.《人用药品注册技术要求国际协 [17] FDA. Pediatric research equity act[EB/OL].[2020-09-20].
调会议 E11(R1)儿童药物临床研究指南》要点解读[J]. https://www.fda.gov/drugs/development-resources/pedia-
中国临床药理学杂志,2020,36(21):3551-3554. tric-research-equity-act-prea.
[ 7 ] ICH. Addendum to Ich E11:clinical investigation of me- [18] FDA. Food and Drug Administration amendments act[EB/
dicinal products in the pediatric population E11(R1)[EB/ OL]. [2020-09-20]. https://www.fda.gov/regulatory-infor-
OL].(2017-08-18)[2020-09-10]. https://database.ich.org/ mation/selected-amendments-fdc-act/food-and-drug-ad-
·1170 · China Pharmacy 2021 Vol. 32 No. 10 中国药房 2021年第32卷第10期